bioAffinity Technologies Inc. announced that it has regained compliance with all applicable Nasdaq continued listing requirements. The company received written notice from Nasdaq confirming that its common stock and warrants will continue to trade on the Nasdaq Capital Market under the symbols BIAF and BIAFW. This follows the company's compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5550(b)(1), which mandates a minimum of $2.5 million in stockholders' equity. The company will be subject to a one-year Mandatory Panel Monitor period, during which any failure to comply with the equity rule could lead to delisting, although a hearing may be requested before any final action.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015832763) on October 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.